Epitope binning analysis for further differentiation of therapeutic antibodies and diagnostic reagen

SPR based biosensors are essential tools in the development of antibody based biotherapeutic drugs, providing a wide range of information on molecular interactions such as yes/no binding, affinity and kinetics. Additionally, the precise epitope where the candidate molecular entity binds on the target molecule is of critical importance from a biologic, functional and intellectual property perspective. This information can be obtained by characterization of lead candidates via epitope binning studies. Antibodies from multiple epitope bins may imply different mechanisms of action. Epitope binning studies can be particularly advantageous when pursuing oligoclonal therapies for cancers or infectious diseases which target more than one biological pathway simultaneously. Thus, the identification of unique and diverse epitopes is not only of importance for discovering antibody binding pairs (e.g. immunoassays), but may also broaden the potential for intellectual property protection.

Speaker:
Robyn Stoller
Field Application Scientist - Biacore

Robyn Stoller is the Biacore Field Application Scientist for Cytiva serving the New England region of the United States. She was trained at the University of Minnesota, and has been working with biophysical techniques for 10 years.